Who owns Keros Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KROS from SEC Form 13F filings across 132 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 132 institutions disclosed 18.6M shares of Keros Therapeutics, Inc. worth $198.6M — about 93.7% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
132
13F holders
$198.6M
value, 2026 filers
93.7%
of shares outstanding (18.6M sh)
15
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of KROS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2.8M | $29.9M | 0.0% | 14.1% | +15.9% |
| 2 | Nantahala Capital Management, LLC | 1.4M | $15.1M | 0.5% | 7.1% | +3.7% |
| 3 | AQR CAPITAL MANAGEMENT LLC | 967,859 | $10.4M | 0.0% | 4.9% | +138.1% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 833,596 | $8.9M | 0.0% | 4.2% | +0.3% |
| 5 | ORBIMED ADVISORS LLC | 759,155 | $8.1M | 0.2% | 3.8% | 0.0% |
| 6 | FEDERATED HERMES, INC. | 700,427 | $7.5M | 0.0% | 3.5% | +1.6% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 652,635 | $7.0M | 0.0% | 3.3% | -4.3% |
| 8 | MACKENZIE FINANCIAL CORP | 628,438 | $6.7M | 0.0% | 3.2% | +312.2% |
| 9 | Madison Avenue Partners, LP | 626,583 | $6.7M | 0.3% | 3.2% | 0.0% |
| 10 | Qube Research & Technologies Ltd | 608,837 | $6.5M | 0.0% | 3.1% | -16.0% |
| 11 | JACOBS LEVY EQUITY MANAGEMENT, INC | 605,445 | $6.5M | 0.0% | 3.1% | -14.3% |
| 12 | STATE STREET CORP | 541,193 | $5.8M | 0.0% | 2.7% | -3.7% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 510,841 | $5.5M | 0.0% | 2.6% | -25.0% |
| 14 | DIMENSIONAL FUND ADVISORS LP | 460,541 | $4.9M | 0.0% | 2.3% | +43.3% |
| 15 | CITADEL ADVISORS LLC | 396,098 | $4.2M | 0.0% | 2% | -2.6% |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 359,086 | $3.8M | 0.0% | 1.8% | -20.8% |
| 17 | D. E. Shaw & Co., Inc. | 267,460 | $2.9M | 0.0% | 1.4% | -47.5% |
| 18 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 265,017 | $2.8M | 0.0% | 1.3% | +35.9% |
| 19 | Nuveen, LLC | 247,756 | $2.7M | 0.0% | 1.3% | -5.5% |
| 20 | ADAR1 Capital Management, LLC | 246,818 | $2.6M | 0.1% | 1.2% | +153.6% |
| 21 | TWO SIGMA INVESTMENTS, LP | 246,649 | $2.6M | 0.0% | 1.2% | -32.2% |
| 22 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 233,175 | $2.5M | 0.0% | 1.2% | -60.5% |
| 23 | MILLENNIUM MANAGEMENT LLC | 184,822 | $2.0M | 0.0% | 0.9% | +73.0% |
| 24 | GOLDMAN SACHS GROUP INC | 177,846 | $1.9M | 0.0% | 0.9% | -20.8% |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 158,712 | $1.7M | 0.0% | 0.8% | -11.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.